Skip to main content
. 2018 Aug 2;20(12):2830–2839. doi: 10.1111/dom.13463

Figure 2.

Figure 2

Persistence rates A, by oral antidiabetic drug (OAD) class in all patients, B, by estimated glomerular filtration rate (eGFR) stage of renal impairment (RI) and by OAD class for each eGFR stage of RI, C, stage G1, D, stage G2, E, stage G3 and F, stage G4+. α‐GI, α‐glucosidase inhibitor; BG, biguanide; CI, confidence interval; DPP‐4, dipeptidyl peptidase‐4; SU; sulphonylurea; TZD, thiazolidinedione